Yahoo Finance

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

OCALA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Safety Committee approval to proceed with the Phase 2 portion of the ...
Nature

Erasmus MC Cancer Institute

Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Nature Careers is visited by over 180,000 ...
Nature

Erasmus University Medical Center (Erasmus MC)

Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Nature Careers is visited by over 180,000 ...
Nasdaq

AIM ImmunoTech and Erasmus MC Announce Progress on Phase 2 Trial for Ampligen® and Imfinzi® in Late-Stage Pancreatic Cancer

AIM ImmunoTech announced that CEO Tom Equels and Professor Casper H.J. van Eijck discussed the recently approved Phase 2 trial of AIM's Ampligen® (rintatolimod) combined with AstraZeneca's Imfinzi® ...